# Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer

> **NCT06204523** · — · UNKNOWN · sponsor: **Regina Elena Cancer Institute** · enrollment: 167 (estimated)

## Conditions studied

- DNA Damage
- Gastric Cancer

## Interventions

- **DIAGNOSTIC_TEST:** investigated biomarkers regarding the efficacy of first-line chemotherapy

## Key facts

- **NCT ID:** NCT06204523
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-26
- **Primary completion:** 2023-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 167 (ESTIMATED)
- **Last updated:** 2024-01-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204523, "Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06204523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*